185,390 Shares in Revolution Medicines, Inc. $RVMD Bought by Artia Global Partners LP

Artia Global Partners LP purchased a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 185,390 shares of the company's stock, valued at approximately $34,720,000. Revolution Medicines makes up 6.4% of Artia Global Partners LP's portfolio, making the stock its 5th largest holding. Artia Global Partners LP owned 0.09% of Revolution Medicines at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in RVMD. Contravisory Investment Management Inc. purchased a new position in shares of Revolution Medicines during the second quarter valued at about $32,000. Global Retirement Partners LLC lifted its holdings in Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company's stock worth $32,000 after buying an additional 361 shares during the period. Torren Management LLC bought a new stake in Revolution Medicines during the 4th quarter valued at approximately $33,000. Johnson Financial Group Inc. bought a new stake in Revolution Medicines during the 2nd quarter valued at approximately $37,000. Finally, Arax Advisory Partners purchased a new position in shares of Revolution Medicines during the 4th quarter worth approximately $38,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, COO Margaret A. Horn sold 60,400 shares of the company's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $160.17, for a total value of $9,674,268.00. Following the transaction, the chief operating officer owned 158,222 shares in the company, valued at approximately $25,342,417.74. This represents a 27.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Stephen Michael Kelsey sold 4,175 shares of the stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total transaction of $651,801.00. Following the sale, the insider owned 291,876 shares in the company, valued at approximately $45,567,681.12. The trade was a 1.41% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 212,497 shares of company stock valued at $38,206,486. 7.60% of the stock is owned by company insiders.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: The FDA approval expands Revolution Medicines beyond clinical development and opens a potentially significant revenue opportunity in a cancer with substantial unmet treatment needs. The drug’s accelerated review and favorable efficacy profile reinforce investor confidence in the company’s RAS/MAPK-focused platform. Reuters FDA approval article
• Positive Sentiment: Management priced RASONQUE at approximately $39,800 per month, establishing a high-value commercial product and giving investors an initial benchmark for potential sales. RASONQUE pricing article
• Positive Sentiment: TD Cowen upgraded RVMD to “strong buy,” while other analysts have maintained bullish ratings and price targets above recent trading levels. Institutional ownership and reported purchases by some funds also provide supportive sentiment.
• Neutral Sentiment: The stock’s reaction has been relatively restrained despite the approval, likely because investors had anticipated the decision and RVMD already trades at an elevated valuation after a substantial run-up.
• Negative Sentiment: The $39,800 monthly list price could intensify scrutiny from insurers, policymakers and patients, potentially limiting access or slowing adoption. This pricing concern may be offsetting some of the enthusiasm surrounding the FDA decision. Pricing impact article
• Negative Sentiment: Insider Mark Goldsmith sold 80,000 shares for about $16.7 million, reducing his holdings by roughly 23%. Although one insider transaction is not necessarily a change in fundamentals, it can create a modest sentiment overhang after the stock’s sharp appreciation. Insider sale article

Revolution Medicines Trading Up 1.9%

Revolution Medicines stock opened at $215.44 on Thursday. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. The business's fifty day simple moving average is $191.27 and its two-hundred day simple moving average is $147.30. Revolution Medicines, Inc. has a 12 month low of $35.64 and a 12 month high of $220.34. The company has a market capitalization of $46.18 billion, a price-to-earnings ratio of -24.43 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.04) by ($1.02). During the same period in the prior year, the company posted ($1.31) EPS. As a group, equities analysts predict that Revolution Medicines, Inc. will post -8.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on RVMD. Weiss Ratings restated a "sell (d-)" rating on shares of Revolution Medicines in a research note on Friday, July 17th. Truist Financial raised their price objective on Revolution Medicines from $210.00 to $231.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Wolfe Research restated an "outperform" rating and set a $220.00 target price on shares of Revolution Medicines in a report on Monday, August 10th. Royal Bank Of Canada upped their target price on shares of Revolution Medicines from $182.00 to $203.00 and gave the stock an "outperform" rating in a research report on Thursday, August 6th. Finally, Sanford C. Bernstein increased their price target on shares of Revolution Medicines from $151.00 to $179.00 and gave the stock a "market perform" rating in a research note on Friday, August 21st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $167.89.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source